Samsung Biologics Co.,Ltd. (KRX:207940)
South Korea · Delayed Price · Currency is KRW 1,182,000
-24,000 (-1.99%)
Oct 14, 2026, 3:30 PM KST
Samsung Biologics Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 54,655,110 | 78,463,162 | 67,544,125 | 54,092,240 | 58,433,854 | 59,746,994 | |
Market Cap Growth | -24.27% | 16.17% | 24.87% | -7.43% | -2.20% | 9.32% |
Enterprise Value | 53,683,446 | 77,724,732 | 67,525,830 | 54,470,491 | 57,778,382 | 59,669,231 |
Last Close Price | 1206000.00 | 1683558.75 | 1195725.91 | 957588.72 | 1034447.81 | 1125808.67 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 28.40 | 43.97 | 62.35 | 63.07 | 73.22 | 151.80 |
Forward PE | 27.13 | 42.21 | 62.18 | 60.08 | 82.37 | 112.20 |
PS Ratio | 10.89 | 17.22 | 19.31 | 14.64 | 19.47 | 38.10 |
PB Ratio | 6.67 | 10.53 | 6.19 | 5.50 | 6.50 | 11.97 |
P/TBV Ratio | 6.73 | 10.62 | 8.52 | 8.23 | 10.14 | 12.05 |
P/FCF Ratio | 34.25 | 91.66 | 189.90 | 80.60 | - | 1235.91 |
P/OCF Ratio | 22.91 | 34.91 | 40.71 | 32.46 | 61.31 | 131.43 |
PEG Ratio | 1.32 | 1.46 | 3.24 | 3.45 | 8.15 | 3.45 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 10.70 | 17.06 | 19.31 | 14.74 | 19.25 | 38.05 |
EV/EBITDA Ratio | 19.37 | 28.76 | 35.16 | 33.97 | 44.72 | 85.35 |
EV/EBIT Ratio | 23.51 | 37.56 | 51.10 | 48.91 | 58.74 | 111.05 |
EV/FCF Ratio | 33.65 | 90.79 | 189.85 | 81.16 | - | 1234.30 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.15 | 0.12 | 0.14 | 0.19 | 0.28 | 0.26 |
Debt / EBITDA Ratio | 0.44 | 0.34 | 0.77 | 1.19 | 1.95 | 1.85 |
Debt / FCF Ratio | 0.76 | 1.08 | 4.18 | 2.85 | - | 26.74 |
Net Debt / Equity Ratio | -0.12 | -0.07 | 0.01 | -0.01 | -0.08 | -0.02 |
Net Debt / EBITDA Ratio | -0.34 | -0.21 | 0.08 | -0.09 | -0.53 | -0.11 |
Net Debt / FCF Ratio | -0.60 | -0.65 | 0.44 | -0.22 | 179.20 | -1.63 |
Asset Turnover | 0.34 | 0.32 | 0.21 | 0.23 | 0.24 | 0.22 |
Inventory Turnover | 0.87 | 0.83 | 0.66 | 0.76 | 0.91 | 1.02 |
Quick Ratio | 0.95 | 0.85 | 0.35 | 0.50 | 0.76 | 1.24 |
Current Ratio | 1.80 | 1.74 | 1.43 | 1.33 | 1.54 | 2.55 |
Return on Equity (ROE) | 18.53% | 17.59% | 10.03% | 9.12% | 11.42% | 8.21% |
Return on Assets (ROA) | 9.57% | 9.11% | 4.95% | 4.27% | 5.01% | 4.67% |
Return on Invested Capital (ROIC) | 23.55% | 17.57% | 9.57% | 9.48% | 11.77% | 7.98% |
Return on Capital Employed (ROCE) | 24.00% | 24.30% | 9.80% | 9.40% | 7.90% | 7.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 3.56% | 2.27% | 1.60% | 1.59% | 1.37% | 0.66% |
FCF Yield | 2.92% | 1.09% | 0.53% | 1.24% | -0.01% | 0.08% |
Buyback Yield / Dilution | 5.91% | 5.85% | - | -1.95% | -5.51% | - |